AngioDynamics to Sponsor Symposium on First Human Clinical Experience with IRE TechnologyQUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 16, 2009--AngioDynamics Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it will sponsor a symposium in New York City on January 22 during which doctors who have performed procedures using the Company's recently-introduced NanoKnife^™ system will share their experiences and patient outcomes.

NanoKnife is the first product offered by AngioDynamics that uses the new, potentially groundbreaking irreversible electroporation (IRE) technology. IRE technology is a non-thermal ablation technique for the resection of soft tissue. It has been described as "surgery at the cellular level." The NanoKnife system uses electrical fields to create nano-scale defects in the membranes of targeted soft tissue, causing cell death only in the targeted tissue, without destroying critical structures such as ducts, blood vessels and nerves nearby.

For further information, please contact Jenifer Kirtland at (415) 896-2005 or Chris Gale at (646) 201-5431.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

    CONTACT: AngioDynamics, Inc.
             D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
             jgersuk@AngioDynamics.com
             or
             EVC Group, Inc.Doug Sherk, 415-896-6820 (Investor Relations)
             dsherk@evcgroup.com
             Jenifer Kirtland, 415-896-6820 (Investor Relations)
             jkirtland@evcgroup.com
             Chris Gale, 646-201-5431 (Media)
             cgale@evcgroup.com

    Source: AngioDynamics Inc.